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hypothermiaTo the Editor: Pre-clinical and clinical hypothermia trials cooling
subjects between 18C and 33C have suggested potential delete-
rious prothrombotic effects (1). These data have raised major
clinical concerns when considering that a large proportion of car-
diac arrest survivors will undergo primary percutaneous coronary
interventions (PPCIs). Moreover, in previous small clinical series
analyzing the effect of therapeutic hypothermia (TH) in patients
who undergo PPCI, it was observed that there was an increased rate
of stent thrombosis (ST) in TH- compared with non–TH-treated
patients (2). The aim of the present study was to determine whether
there is a relationship between TH and ST.
We retrospectively reviewed the prospective database of the
Hospital Universitario La Paz, Madrid, Spain. All patients were
admitted consecutively between January 2008 and December 2012
after a PPCI with stent implantation for an ST-segment elevation
acute coronary syndrome (STE-ACS), and we divided them into
groups based on their exposure to TH. The hospital protocol
standardized the use of double antiplatelet therapy before PPCI,Baseline Features and In-Hospital Managemen
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.administered orally in the PPCI-only group, and a combination of
intravenous aspirin plus crushed P2Y12 inhibitor through the
nasogastric tube in the PPCI-TH group. The choice of anti-
thrombotic regimen was made at the discretion of the treating
physician. In the PPCI-TH group, cooling started as soon as
possible before the procedure, ﬁrst with intravenous cold saline
followed by the use of an automated cooling device. The target
temperature (32C to 34C) was selected by the treating physician
and maintained for 24 h, after which a controlled rewarming was
set to reach 37C in 12 to 24 h.
The incidence of ST was compared between the PPCI-TH and
PPCI-only groups. Our analysis comprised both deﬁnitive/prob-
able as well as acute/subacute ST. The classiﬁcation followed the
deﬁnition of the Academic Research Consortium (3). The insti-
tutional ethics review committee approved the present analysis.
Continuous variables are presented as mean  SD and were
compared with the use of the Student t test; variables that were not
normally distributed were described as medians and interquartilet
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940ranges, and differences were analyzed with the Kruskal-Wallis
method. Categorical variables were compared by the chi-square
test or Fisher exact test.
A total of 1,414 PPCI for STE-ACS were performed during
the study period; in 77 patients, TH was used due to a comatose
state after cardiac arrest. The access site for the PPCI was always
femoral in the PPCI-TH group and was radial in 59% of the
PPCI-only group. Baseline characteristics and in-hospital man-
agement are shown in Table 1. All patients received a P2Y12
inhibitor. Clopidogrel was more commonly used in the PPCI-
only group, whereas the PPCI-TH group received signiﬁcantly
more prasugrel. Aspirin was not administered to 33 (2.5%) pa-
tients in the PPCI-only group and 1 (1.3%) patient in the PPCI-
TH group, mainly due to allergy or recent gastrointestinal
bleeding. Both loading and maintenance doses of aspirin in all of
the PPCI-TH–group patients were given intravenously. Glyco-
protein IIb/IIIa inhibitors were more commonly used in the
PPCI-only group.
A mean of 2  1.2 stents were implanted in both groups, with an
overall incidence of ST of 2.3% (n ¼ 32). Among the patients
experiencing ST, 30 (2.3%) were in the PPCI-only group: 17
(1.2%) were acute and 13 (1.0%) were subacute. In the PPCI-TH
group, there were only 2 (2.7%) ST: 1 deﬁnitive acute and 1
probable subacute. Major bleeding, according to GRACE (Global
Registry of Acute Coronary Events) deﬁnition (4), was observed in
6 (8.0%) patients in the PPCI-TH group as compared with 17
(1.3%) in the PPCI-only group (p < 0.001).
All-cause mortality at 30 days of follow-up was signiﬁcantly
higher in the PPCI-TH group than in the PPCI-only group (n¼ 33
[44%] vs. 65 [4.9%], p< 0.001). In the PPCI-THgroup, 31 patients
had a reliable cause of death. Eleven arrived at the hospital in
cardiogenic shock that did not improve despite successful revascu-
larization, and died early due to multiple organ failure (MOF)
without any acute decompensation; 1 died due to liver rupture
related to resuscitation maneuvers; 1 died of unexplained cause
(suspected sepsis), and post-mortem examination revealed absence
of ST; 1 died of brain death; and 17 died due to the withdrawal of
life-sustaining treatment secondary to severe post-anoxic encepha-
lopathy. The other 2 deaths were classiﬁed as ST: 1 deﬁnite acute ST
in a clopidogrel-treated patient complicated with retroperitoneal
bleeding after a new PPCI, and 1 subacute probable ST that died on
the 25th day of evolution due to MOF.
It has been suggested that TH-treated patients may have an
increased risk of ST (2), mainly due to MOF and lower
liver metabolism of drugs that inhibit the ADP P2Y12 receptors
and thromboxane A2 synthesis. In the present observational study,
even under the prelude of greater hemodynamic support and a
higher frequency of hemorrhagic complications in the PPCI-TH–
treated patients, the incidence of ST was almost identical to that of
patients not treated with TH. Therefore, and under the need of
further prospective trials, we believe that adequate antithrombotic
management could be achieved in this population with both the
progressive introduction of third-generation P2Y12 inhibitors and
consideration that the route (intravenous aspirin and crushed
nasogastric P2Y12) (5) and time (before PPCI) of administration
may inﬂuence the ﬁnal result.
In our study, the incidence of ST under the effects of TH is
less than that observed in previous series and similar to that expected
in standard PPCI-treated patients. The described prothrombotic
effects of TH are not clinically relevant in patients treated according
to general recommendations.*Sandra O. Rosillo, MD
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Temporal MicroRNA
ProﬁlesLiebetrau et al. (1) used serial sampling in patients undergoing
transcoronary ablation of septal hypertrophy to determine the
temporal release of microRNAs (miRNAs) after cardiac injury.
This model offers the advantage that the time of onset of myocardial
damage is precisely known. However, heparin is routinely admin-
istered during intra-arterial coronary interventions, including septal
ablation (2). Others (3) and we (4) have recently shown that even a
single heparin bolus is sufﬁcient to signiﬁcantly alter measurements
of miRNA by quantitative polymerase chain reaction, in particular
the spike-in C. elegans control, Cel-miR-39, that was also used for
normalization in the study by Liebetrau et al. (1).
